Alzheimer's Disease Clinical Trial
Official title:
Effect of Activity on Sleep of Cognitively-Impaired Veterans
Sleep-activity rhythm disturbance is a prevalent, disabling symptom in cognitively-impaired (CI) elders. Their nocturnal sleep is light and inefficient with frequent awakenings. Multiple short daytime napping episodes interfere with daytime activity and functioning. Daytime disruptive behaviors, such as pacing, hitting, and cursing are related significantly to sleep-activity rhythm disturbance. Medical treatment for sleep and behavior disturbances with benzodiazepines or antipsychotic medications has proven minimally effective and has serious side effects such as impairments in cognition, memory, coordination, and balance, tolerance and severe rebound insomnia, and tardive dyskinesia.
Background:
Sleep-activity rhythm disturbance is a prevalent, disabling symptom in cognitively-impaired
(CI) elders. Their nocturnal sleep is light and inefficient with frequent awakenings.
Multiple short daytime napping episodes interfere with daytime activity and functioning.
Daytime disruptive behaviors, such as pacing, hitting, and cursing are related significantly
to sleep-activity rhythm disturbance. Medical treatment for sleep and behavior disturbances
with benzodiazepines or antipsychotic medications has proven minimally effective and has
serious side effects such as impairments in cognition, memory, coordination, and balance,
tolerance and severe rebound insomnia, and tardive dyskinesia.
Objectives:
The degree of daytime sleepiness in elders may reflect a reduction in the purposive
physical, cognitive, and affective activities that previously sustained daytime alertness
and promoted psychological well-being. For some institutionalized elders, living in a
physically, cognitively, and emotionally understimulating setting may induce excessive
napping during the day with a subsequent adverse impact on circadian sleep-wake patterns.
Concrete, reality-based activities may counter napping by keeping residents with dementia
involved in the world around them and helping them meet psychological, physical, and social
needs. Our pilot study with five nursing home residents demonstrated that activities timed
to occur during usual naptime and tailored to residents� interests and their remaining
abilities improved nocturnal sleep. Our other research has shown that engaging residents in
meaningful activity improved their psychological well-being and decreased certain types of
disruptive behaviors.
Methods:
We tested the effect of an Individualized Activity Intervention timed to occur when the
resident usually napped in the daytime on nocturnal sleep as measured by actigraphy in CI
nursing home residents. Examples of individualized activities include objects for tactile
and visual stimulation, arts and crafts, and games. We also tested the effect of the
intervention on psychological well-being and disruptive behavior, and measured its cost.
After the collection of baseline sleep, disruptive behavior, and psychological well-being
data for five days, residents were randomly assigned to the Individualized Activity
Intervention or to a usual care control condition for 21 days. On days 17-21, the research
assistant repeated the outcome measures.
Status:
Secondary data analysis on psychological well-being, disruptive behavior, and cost of the
intervention is in progress.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT01922258 -
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
|
Phase 3 |